The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
about
Eosinophilia in Hematologic DisordersEosinophilic myeloproliferative disordersTargeting the PDGF signaling pathway in tumor treatmentIdentification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRATherapeutic approaches to patients with hypereosinophilic syndromes.How I treat hypereosinophilic syndromes.The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.Platelet-derived growth factors and their receptors in normal and malignant hematopoiesisGeneration of the Fip1l1-Pdgfra fusion gene using CRISPR/Cas genome editing.Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
P2860
Q26799611-F3438C04-2301-433B-A85D-DD3FE17E16F5Q33881283-045D6BF3-566F-48AE-A087-7CF044EC78D2Q34393461-9C6A62C7-2BBE-4398-9670-A62A5517F1BBQ35114558-A5ECCD6A-8FA3-43DC-BA6F-6A22B02ED4ACQ35857340-2B21B0DA-0375-4AF3-9DC3-B93B32D3D489Q36000858-D994546F-7192-4A52-B271-A3062D0D8795Q37061044-58456AF2-4F5C-44FF-AE2E-6B796895FCF7Q37865381-F9C3A34C-58B4-4194-8634-D41DBA6A8537Q38131481-EF56A73B-F268-40B4-A112-845BC89538FCQ38833725-50003CE9-93C0-4CAC-8320-F7685A50C3CEQ40115606-9889665C-EB66-4C9C-9047-B28AFA03622AQ40401088-4CA35199-E38D-4BA9-8074-7139AA656FCAQ42126072-9275A246-D845-4B3B-B4CF-8DACE864D808Q42148688-06A0C46F-330D-410F-9F1B-BAB923A3E770Q42721685-13703BB1-C653-4533-B673-73178592E162Q42829472-93659D9E-E399-46F3-94D0-5C98C313E553Q53227886-A60F7951-6BA2-4368-821D-BB7444F78370
P2860
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The low frequency of clinical ...... ase domain mutations in vitro.
@en
The low frequency of clinical ...... ase domain mutations in vitro.
@nl
type
label
The low frequency of clinical ...... ase domain mutations in vitro.
@en
The low frequency of clinical ...... ase domain mutations in vitro.
@nl
prefLabel
The low frequency of clinical ...... ase domain mutations in vitro.
@en
The low frequency of clinical ...... ase domain mutations in vitro.
@nl
P2093
P2860
P356
P1433
P1476
The low frequency of clinical ...... ase domain mutations in vitro.
@en
P2093
N von Bubnoff
S P Gorantla
T M Oliveira
P2860
P2888
P304
P356
10.1038/ONC.2010.476
P407
P577
2010-10-25T00:00:00Z